# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Fyodor Dostoevsky (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI018-SYN
- Date: 2026-02-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Agnes Lindahl, MD
- Calendar frame: modern shifted

## What we are working on

- He wants the seizures to stop interrupting his writing and his deadlines **S**
- He wants to stop losing money at roulette and to pay off his debts **S**

## Your goals

- Reach the lamotrigine maintenance dose without rash by the two-month visit. Target: 2026-05-05. Recorded outcome: Maintenance dose of 100 mg twice daily reached after six weeks; no rash. **S**
- No seizures for six months after reaching the maintenance dose. Target: 2026-10-06. Recorded outcome: Not met: one generalized tonic-clonic seizure about five months after reaching the maintenance dose, after missed doses and a night without sleep; the six-month count restarts. **S**
- Casino and online self-exclusion and a bank gambling block in place by the four-week visit. Target: 2026-03-03. Recorded outcome: Self-exclusion from casinos in the state and from licensed online sites, and a gambling block on his bank cards, in place. **S**
- No gambling through the eight-month visit. Target: 2026-10-06. Recorded outcome: Not met: no gambling for about seven months, then a lapse while traveling abroad, outside the reach of his self-exclusion; treatment intensified. **S**
- Written seizure action plan, safety counseling, and a SUDEP discussion completed by the four-week visit. Target: 2026-03-03. Recorded outcome: Plan written and shared with two friends; SUDEP discussed with the neurologist. **S**

## What we agreed to do

- Neurology consultation for seizure classification, EEG and MRI review, and the choice of antiseizure medicine. Guideline: Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015); Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology (2017); ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology (2017) **S**
- Antiseizure medicine: lamotrigine with slow titration, rash teaching, 30-day supplies, a pill organizer and phone alarms, a seizure diary, and levels only when they would change care. Guideline: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018); The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy (2021) **S**
- Seizure safety at every visit: triggers (sleep loss, alcohol, overwork), showers rather than baths, no swimming or heights alone, no driving until seizure-free and cleared by his neurologist, a written seizure action plan for friends, and a SUDEP discussion. Guideline: Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015); Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors (2017) **S**
- Gambling-disorder treatment: cognitive behavioral therapy with a gambling-disorder therapist, self-exclusion, a bank gambling block, Gamblers Anonymous, and free debt counseling. Guideline: Psychological therapies for pathological and problem gambling (2012); Gambling disorder (2019) **S**
- Mood and safety: PHQ-9 at intake and every two to four months, GAD-7 at intake and with any change, and a suicide-risk review with the 988 Suicide & Crisis Lifeline at every visit. Guideline: ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Bone health: baseline vitamin D; lamotrigine is not an enzyme inducer, so no DXA scan is needed unless an enzyme-inducing medicine is added. Guideline: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018) **S**

## Follow-up

- 2026-02-03: Establishing care after recurrent seizures: seizure history, baseline tests, EEG and MRI orders, seizure safety, and gambling-disorder assessment with a safety assessment **S**
- 2026-03-03: Four-week follow-up with neurology consultation; EEG and MRI reviewed and lamotrigine started **S**
- 2026-05-05: Two-month review: lamotrigine at maintenance dose, rash and mood check, and gambling treatment progress **S**
- 2026-07-07: Four-month review of seizure control, mood, and gambling recovery **S**
- 2026-10-06: Eight-month review after a breakthrough seizure and a gambling lapse while traveling **S**
- 2026-10-20: Adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
